(Q35539510)

English

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries

scientific article published on 6 January 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

25

object named as

Roberto Muga

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

12

object named as

Ard van Sighem

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

5

object named as

Caroline Sabin

0 references

Dominique Costagliola

29

object named as

Dominique Costagliola

0 references

object named as

Amy Justice

7

0 references

Santiago Pérez-Hoyos

object named as

Santiago Pérez-Hoyos

24

0 references

François Dabis

26

object named as

François Dabis

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

0 references

Maria José Amengual

1 reference

ORCID Public Data File 2021

1 reference

ORCID Public Data File 2021

Arantza Sanvisens

1 reference

ORCID Public Data File 2021

1 reference

ORCID Public Data File 2021

Andrew N Phillips

3

object named as

Andrew Phillips

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Jonathan Sterne

11

object named as

Jonathan A C Sterne

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

13

object named as

Peter Reiss

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

author name string

HIV-CAUSAL Collaboration

1

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Lauren E Cain

2

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Ashley Olson

4

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Sophie Jose

6

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Janet Tate

8

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Roger Logan

9

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

James M Robins

10

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

James Young

14

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Jan Fehr

15

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Giota Touloumi

16

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Vasilis Paparizos

17

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Anna Esteve

18

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Jordi Casabona

19

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Susana Monge

20

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Santiago Moreno

21

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Rémonie Seng

22

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Laurence Meyer

23

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Marie-Anne Vandenhende

27

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Sophie Abgrall

28

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Miguel A Hernán

30

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

language of work or name

0 references

publication date

6 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

60

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

1262-1268

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447777

27 July 2018

Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447777

27 July 2018

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447777

27 July 2018

Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447777

27 July 2018

Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447777

27 July 2018

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447777

27 July 2018

Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447777

27 July 2018

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447777

27 July 2018

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447777

27 July 2018

1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447777

27 July 2018

The effect of efavirenz versus nevirapine-containing regimens in the HIV-CAUSAL Collaboration: reply to Llibre and Podzamczer and additional results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447777

26 September 2018

Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447777

26 September 2018

Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447777

26 September 2018

A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447777

26 September 2018

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447777

26 September 2018

A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447777

26 September 2018

Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4447777

26 September 2018

Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU1167

21 January 2018

Easy SAS calculations for risk or prevalence ratios and differences

1 reference

https://pubmed.ncbi.nlm.nih.gov/25567330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/CID/CIU1167

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35539510&oldid=1751776974"